AstraZeneca Plc

AstraZeneca Plc

AstraZeneca Plc

Overview
Date Founded

1992

Headquarters

Cambridge Biomedical Campus,1 Francis Crick Avenue,Cambridge, Cambridgeshire CB2 0AA

Type of Company

Public

Employees (Worldwide)

76.1K

Industries

Pharmaceuticals
Wholesale: Medical Supplies & Pharmaceuticals
Wholesale: Consumer Durables
Other Manufacturing
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at AstraZeneca Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Director & Chief Executive Officer

Executive Director & Chief Financial Officer

Executive Vice President, Human Resources & General Counsel

Chief Compliance Officer

Chief Strategy Officer

Executive Vice President, BioPharmaceuticals Business Unit

Executive Vice President, Oncology R&D

Executive Vice President, Operations & Information Technology

Executive Vice President, Oncology Business Unit

Executive Vice President, BioPharmaceuticals R&D

Board of Directors

Chairman at AstraZeneca Plc

Former Chief Executive Officer at Avon Products, Inc.

Former President & Chief Executive Officer at Investor AB (Investment Company)

Executive Director & Chief Executive Officer at AstraZeneca Plc

Chairman at International Institute for Management Development

Chairman, Department of Clinical Oncology at The Chinese University of Hong Kong - Faculty of Medicine

President, Best Buy Health at Best Buy Co., Inc.

Former Head-Genetics & Epidemiology Division at The Institute of Cancer Research

Executive Director & Chief Financial Officer at AstraZeneca Plc

Paths to AstraZeneca Plc
Potential Connections via
Relationship Science
You
AstraZeneca Plc
Owners & Shareholders
Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Details Hidden

BIM-UK utilizes their market insights, global reach, proprietary technology, culture of information sharing and focus on risk management to deliver performance in all market environments. For their equity investments, the firm utilizes style-neutral (core and high performance), value and growth processes. They have combined a top-down and bottom-up approach for their fixed-income and balanced products. The fixed-income investment team specializes in particular market segments and focuses on quantitative analysis. Their Pinpoint system enables them to identify and track fixed-income issuers and credits. Investment teams are autonomous. Process implementation is formalized through investment committees and is reviewed monthly with the CIO, the head of performance and risk management and team leaders.

Details Hidden

GQG Partners is a long-term investor that aims to deliver superior risk-adjusted returns and capital appreciation over a full market cycle by investing primarily in the equity securities of both US and non-US issuers that they believe have durable earnings potential that is undervalued by the market. Their portfolios are diversified by country and sector, but are not constrained by any benchmark index. The firm typically invests in common and preferred stock and other publicly traded equity securities. With an investment horizon of five years, portfolio holdings tend to be stable over time. GQG Partners pursues a bottom-up fundamental research process to stock selection. The firm sells companies when their risks or opportunities fundamentally changes, or when the stock price no longer reflects a good value. They will also sell companies when they find more attractive alternatives.

Recent Transactions
Details Hidden

AstraZeneca Plc, Alexion Pharmaceuticals, Inc. purchase Caelum Biosciences, Inc. from Fortress Biotech, Inc.

Details Hidden

AstraZeneca Plc purchases Alexion Pharmaceuticals, Inc.

Details Hidden

Taiyo Holdings Co., Ltd., Taiyo Pharma Co., Ltd. purchase AstraZeneca KK /4 Pharmaceutical Products from AstraZeneca Plc

Transaction Advisors
Legal Advisor

Advised onZeneca Group Plc purchases Astra AB resulting in a new company AstraZeneca Plc

Legal Advisor

Advised onAstraZeneca Plc purchases Ardea Biosciences, Inc.

Legal Advisor

Advised onAstraZeneca Plc purchases MedImmune LLC

Legal Advisor

Advised onAstraZeneca Plc purchases Ardea Biosciences, Inc.

Legal Advisor

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Legal Advisor

Advised onAstraZeneca Plc purchases ZS Pharma, Inc.

Advisors & Consultants
Legal Advisor

Chief Legal Officer & Secretary at Comcast Corporation

Legal Advisor

Partner at Sidley Austin LLP

Legal Advisor

Senior Counsel at Davis Polk & Wardwell LLP

Clients

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.

Key Stats and Financials As of 2020
Market Capitalization
$180B
Total Enterprise Value
$139B
Earnings Per Share
$2.52
TEVNet Income
42.23x
Enterprise Value EBITDAOperating
17.8x
EBITDAMargin
27.47%
Enterprise Value / Sales
4.89x
Debt TEV
0.14x
Three Year Compounded Annual Growth Rate Of Revenue
7.25%
Revenue
$28.5B
Total Debt
$19.8B
Total Equity
$15.2B
Net Profit
$3.3B
EBITDA
$7.83B
Non-Profit Donations & Grants
$500K - $1M
2018
$5,000 +
2017
Investments
Details Hidden

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Malvern, PA.

Details Hidden

Rani Therapeutics LLC develops a oral biotherapeutics technology for the oral delivery of drug molecules, including peptides, proteins, and antibodies. Its products include TNFa Inhibitors, Parathyroid Hormone, Human Growth Hormone, Somatostatin, and Basal Insulin. The company is headquartered in San Jose, CA.

Details Hidden

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Investors
Details Hidden

General Partner at Ventech SA

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Suppliers
AptarGroup, Inc. Hospitals & Patient Services | Crystal Lake, IL

AptarGroup, Inc. develops manufactures and sales of consumer product dispensing systems. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Sodexo SA Other Business & Consulting Services | Issy-les-moulineaux, France

Sodexo SA engages in the provision of on-site services, benefits and rewards services, and personal and home care services. It offers integrated solutions which cover a variety of working and living environments and are available in client segments which include corporate, health care, education, defense, remote sites, justice services, seniors, and sports and leisure. Sodexo was founded by Pierre Bellon in 1966 and is headquartered in Issy-les-Moulineaux, France.

Alliance Data Systems Corp. Other Business & Consulting Services | Plano, Texas

Alliance Data Systems Corp. engages in the provision of data-driven and transaction-based marketing, customer loyalty and payment solutions. It operates through the following segments: LoyaltyOne, Epsilon and Card Services. The LoyaltyOne segment provides coalition and short-term loyalty programs. The Epsilon segment offers end-to-end, integrated marketing solutions. The Card Services offers risk management solutions, account origination, funding, transaction processing, customer care, collections, and marketing services for the company's private label and co-brand credit card programs. The company was founded in 1996 and is headquartered in Columbus, Ohio.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AstraZeneca Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AstraZeneca Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and AstraZeneca Plc.